Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements (2023 and earlier)

Company Profile

Business Address 777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
State of Incorp. NY
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,6953,5873,2142,8101,4101,0391,045
Cash and cash equivalents2,8862,1941,6181,468813535809
Short-term investments2,8091,3931,5971,342597503236
Receivables6,0373,1122,3611,9501,7321,4361,306
Inventory, net of allowances, customer advances and progress billings1,9511,9171,4161,151726399239
Inventory1,9511,9171,4161,151726399239
Other undisclosed current assets3321,164699536467306326
Total current assets:14,0159,7797,6896,4484,3353,1802,915
Noncurrent Assets
Finance lease, right-of-use asset631646 ✕✕✕✕
Property, plant and equipment  2,8902,5762,3592,0831,594
Long-term investments and receivables6,8383,1363,2571,7551,486864632
Long-term investments6,8383,1363,2571,7551,486864632
Deferred income tax assets877859824✕✕✕✕
Other noncurrent assets22316814512778206
Deferred tax assets, net✕✕✕ 506825462
Other undisclosed noncurrent assets2,8512,576 829   
Total noncurrent assets:11,4207,3847,1165,2874,4293,7932,694
TOTAL ASSETS:25,43517,16314,80511,7358,7646,9735,609
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,2071,5221,087772815879644
Accounts payable564476 218178135141
Accrued liabilities38433030116512910486
Employee-related liabilities441466344262192153133
Taxes payable3262049210236 
Other undisclosed accounts payable and accrued liabilities492231392107315252284
Deferred revenue442 592✕✕✕✕
Debt720    127 
Deferred revenue and credits✕✕✕✕320232153
Contract with customer, liability✕✕✕453✕✕✕
Other liabilities 122  0314
Other undisclosed current liabilities5641,053418218   
Total current liabilities:3,9332,6972,0971,4431,1351,241811
Noncurrent Liabilities
Long-term debt and lease obligation1,9802,696714    
Long-term debt, excluding current maturities1,9801,979     
Finance lease, liability 717714✕✕✕✕
Liabilities, other than long-term debt754 905826781931780
Deferred revenue and credits✕✕✕✕629831665
Deferred revenue73 619✕✕✕✕
Contract with customer, liability✕✕✕464✕✕✕
Other liabilities680 286362152100116
Other undisclosed noncurrent liabilities 745 709703352363
Total noncurrent liabilities:2,7343,4411,6191,5341,4851,2831,143
Total liabilities:6,6666,1383,7162,9772,6202,5241,954
Stockholders' equity
Stockholders' equity attributable to parent, including:18,76911,02511,0908,7576,1444,4493,655
Treasury stock, value(8,261)(6,613)(740)(396)(316)(316)(306)
Additional paid in capital8,0886,7164,4293,9123,5133,0303,100
Accumulated other comprehensive income (loss)(26)2921(12)1(13)9
Retained earnings18,96810,8937,3805,2542,9471,748853
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:18,76911,02511,0908,7576,1444,4493,655
TOTAL LIABILITIES AND EQUITY:25,43517,16314,80511,7358,7646,9735,609

Income Statement (P&L) ($ in millions)
Annual | Quarterly

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues16,0728,4977,8636,7115,8724,8604,104
Revenue, net✕✕✕✕4,9344,1163,523
Cost of revenue(2,392)(840)(768)(434)(397)(300)(393)
Cost of goods and services sold(457)(39)(74) (203)(209)(252)
Gross profit:13,6807,6587,0966,2775,4754,5613,711
Operating expenses(4,733)(4,081)(4,886)(3,742)(3,396)(3,230)(2,459)
Other operating income, net46280     
Other undisclosed operating loss(46)(280)     
Operating income:8,9473,5772,2102,5342,0801,3311,252
Nonoperating income (expense)37923421919(1)(1)(27)
Other nonoperating income436291250472466
Interest and debt expense(57)(57)(30)(28)  (19)
Other undisclosed income from continuing operations before equity method investments, income taxes 573028  19
Income from continuing operations before equity method investments, income taxes:9,2693,8102,4292,5542,0791,3301,225
Other undisclosed income from continuing operations before income taxes57      
Income from continuing operations before income taxes:9,3263,8102,4292,5542,0791,3301,225
Income tax expense(1,251)(297)(313)(109)(880)(434)(589)
Net income available to common stockholders, basic:8,0753,5132,1162,4441,199896636
Interest on convertible debt     0 
Net income available to common stockholders, diluted:8,0753,5132,1162,4441,199896636

Comprehensive Income ($ in millions)
Annual | Quarterly

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income:8,0753,5132,1162,4441,199896636
Other comprehensive income (loss)(56)  (6)13(3)(25)
Comprehensive income:8,0203,5132,1162,4381,212892611
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 833  (18)(19)
Comprehensive income, net of tax, attributable to parent:8,0203,5212,1492,4381,212874592

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: